| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H32ClN5O3.C7H8O3S |
| Molecular Weight | 634.187 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(C=C1)S(O)(=O)=O.[H][C@@]23CC[C@@H](C[C@]2([H])C[C@H](NC3)C(=O)OCC(CC)CC)OC4=C(C5=NN=NN5)C(Cl)=CC=C4
InChI
InChIKey=WLTMCPAAIJIZKG-BVNPURGCSA-N
InChI=1S/C23H32ClN5O3.C7H8O3S/c1-3-14(4-2)13-31-23(30)19-11-16-10-17(9-8-15(16)12-25-19)32-20-7-5-6-18(24)21(20)22-26-28-29-27-22;1-6-2-4-7(5-3-6)11(8,9)10/h5-7,14-17,19,25H,3-4,8-13H2,1-2H3,(H,26,27,28,29);2-5H,1H3,(H,8,9,10)/t15-,16+,17-,19-;/m0./s1
Dasolampanel (NGX-426) is an orally available competitive antagonist of the AMPA and kainate receptors. The dug originated at Eli Lilly and Horizon Pharma and was developed for the treatment of migraine and neuropathic pain. Dasalompanel was reduced capsaicin-induced pain and hyperalgesia in human volunteers but failed to achieve positive results in phase 2 clinical trials in patients with pain due to osteoarthritis of the knee and diabetic peripheral neuropathic pain.
Originator
Approval Year
Patents
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
